Since, in addition to IL-17A, IL-17F and IL-17C, which have been shown to mediate experimental cGN [121,122], the treatment of cGN patients with brodalumab could represent a promising future therapeutic strategy. The gene discussed is IL17C; the disease is childhood gender nonconformity.